Amedisys, Inc. (NASDAQ:AMED) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado decreased its position in Amedisys, Inc. (NASDAQ:AMED) by 4.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,440 shares of the health services provider’s stock after selling 151 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Amedisys were worth $316,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Banque Cantonale Vaudoise purchased a new position in shares of Amedisys in the 1st quarter valued at about $60,000. Innealta Capital LLC acquired a new stake in Amedisys in the second quarter valued at approximately $64,000. Covestor Ltd increased its position in shares of Amedisys by 134.2% in the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after buying an additional 447 shares in the last quarter. Signaturefd LLC raised its stake in shares of Amedisys by 88.2% during the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after buying an additional 530 shares during the period. Finally, GAM Holding AG purchased a new position in shares of Amedisys during the 2nd quarter valued at approximately $275,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Performance

AMED opened at $96.63 on Friday. Amedisys, Inc. has a twelve month low of $89.55 and a twelve month high of $98.95. The firm has a market capitalization of $3.16 billion, a PE ratio of -150.98, a PEG ratio of 1.90 and a beta of 0.78. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30. The firm’s 50-day moving average price is $97.61 and its 200 day moving average price is $94.95.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.10. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. The business had revenue of $591.19 million for the quarter, compared to analysts’ expectations of $579.34 million. As a group, sell-side analysts expect that Amedisys, Inc. will post 4.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AMED has been the subject of a number of research analyst reports. Cantor Fitzgerald restated a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a research report on Thursday, July 25th. William Blair cut Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Finally, Deutsche Bank Aktiengesellschaft downgraded Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price on the stock. in a research report on Monday, July 29th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Amedisys presently has an average rating of “Hold” and an average price target of $100.67.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.